BRNS (Barinthus Biotherapeutics) Operating Margin %: 0.00% (As of Mar. 2026)


BRNS Barinthus Biotherapeutics PLC BRNS
52 GF Score
Price $0.66
GF Value $1.12
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics Operating Margin %?

Barinthus Biotherapeutics BRNS -1.48% 52 Operating Margin % is 0.00% as of Mar. 2026. GuruFocus rates BRNS with a GF Score™ of 52/100 and a GF Value™ of $1.12 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Barinthus Biotherapeutics ranks worse than 105820% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Barinthus Biotherapeutics's Operating Income for the three months ended in Mar. 2026 was $-5.93 Mil. Barinthus Biotherapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Barinthus Biotherapeutics's Operating Margin % for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Barinthus Biotherapeutics's Operating Margin % or its related term are showing as below:


BRNS's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.77
* Ranked among companies with meaningful Operating Margin % only.

Barinthus Biotherapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Barinthus Biotherapeutics's Operating Income for the three months ended in Mar. 2026 was $-5.93 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-49.52 Mil.


Barinthus Biotherapeutics  (NAS:BRNS) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Barinthus Biotherapeutics Operating Margin % Related Terms


Barinthus Biotherapeutics Operating Margin % Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics Operating Margin % Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial -15,380.60 -6.27 -10,031.55 -345.90 0.00

Barinthus Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BRNS vs KYNB, SER, PVCT: Operating Margin % Comparison

For the Biotechnology subindustry, Barinthus Biotherapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Barinthus Biotherapeutics Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's Operating Margin % falls into.


BRNS
52GF Score
Barinthus Biotherapeutics PLC BRNS
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Barinthus Biotherapeutics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-63.888 / 0
= %

Barinthus Biotherapeutics's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-5.926 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Barinthus Biotherapeutics (BRNS) has a Operating Margin % of 0.00% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Barinthus Biotherapeutics and its competitors. According to the industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is Barinthus Biotherapeutics' Operating Margin % too high?
Barinthus Biotherapeutics' current Operating Margin % is 0.00%. Based on the distribution chart, Barinthus Biotherapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Operating Margin % compare to KYNB and SER?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 945 companies for Operating Margin %. This places Barinthus Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Barinthus Biotherapeutics (BRNS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.12, compared to a current price of $0.66 — trading 41.1% below its estimated fair value. The current Operating Margin % is 0.00%. Barinthus Biotherapeutics' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Barinthus Biotherapeutics (BRNS), the current Operating Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (BRNS) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of $0.66 is trading 41.1% below its estimated GF Value™ of $1.12. GuruFocus considers Barinthus Biotherapeutics to be Possible Value Trap.

Key valuation signals for BRNS:

  • Operating Margin %: 0.00%
  • GF Value™: $1.12 vs. price of $0.66 (41.1% below fair value)
  • GF Score™: 52/100 with 1 warning sign

No single metric tells the full story. See the BRNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Barinthus Biotherapeutics Business Description

Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
52GF Score

Get the complete analysis for BRNS

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.66
Price
$1.12
GF Value